RTP Mobile Logo
ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care (Webinar Video Proceedings)
Released July 2021

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, gynecologic cancers and lung cancer. Featuring perspectives from Drs Thomas A Abrams, John N Allan, Deborah K Armstrong, Arjun Balar, Virginia F Borges, Harold J Burstein, Robert Dreicer, Justin F Gainor, J Randolph Hecht, Corey J Langer, Krishnansu S Tewari, and Sonali M Smith, moderated by Dr Neil Love. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

    LEARNING OBJECTIVES

    • Consider research data, clinical investigator perspectives and available guideline recommendations to individualize therapy for patients with localized or advanced breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers in the newly diagnosed or relapsed/refractory settings.
    • Recognize oncogenic pathways mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these pathways.
    • Develop a long-term care plan for patients with diverse hematologic cancers and solid tumors, considering age, performance status, tumor-specific biomarker profile, prior exposure to systemic therapy, symptomatology and personal goals of treatment.
    • Discuss the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals or presented at major oncology conferences.
    • Recall clinical trial data with FDA-approved and investigational agents for patients with localized, locally advanced or metastatic breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and, as applicable, refer eligible patients for clinical trial participation.
    • Appraise the common and rare side effects associated with approved and investigational therapeutic agents for cancer, and use this information to develop supportive management plans for patients.
    • Apply clinical research findings in the determination of best-practice selection and sequencing of available treatment modalities for patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
    • Recognize the mechanisms of action, efficacy and safety of approved and investigational therapies to determine the current and potential utility of those agents in clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 6.75 (audio) and 6.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/TxSCOSummit21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/TxSCOSummit21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/TxSCOSummit21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/TxSCOSummit21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Thomas A Abrams, MD
    Senior Physician
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Director, Liver Tumor Center
    Boston, Massachusetts

    Advisory Committee: Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Servier; Ownership Interest: Biogen, Guardant Health, Jounce Therapeutics.

    John N Allan, MD
    Assistant Professor of Medicine
    Weill Cornell Medicine
    New York, New York

    Advisory Committee: AbbVie Inc, Ascentage Pharma, Epizyme, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC; Consulting Agreement: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Janssen Biotech Inc, Pharmacyclics LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc.

    Deborah K Armstrong, MD
    Professor of Oncology
    Professor of Gynecology and Obstetrics
    Skip Viragh Outpatient Cancer Building
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee: AbbVie Inc, Cue Biopharma, Eisai Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Pfizer Inc, Syndax Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

    Arjun Balar, MD
    Associate Professor, Department of Medicine
    Director, Genitourinary Medical Oncology Program
    Medical Director, Clinical Trials Office
    NYU Perlmutter Cancer Center
    New York, New York

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Ownership Interest: GT Biopharma Inc.

    Virginia F Borges, MD, MMSc
    Professor of Medicine with Tenure
    John C and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer
    Deputy Head, Division of Medical Oncology
    Director, Breast Cancer Research Program and
    Young Women’s Breast Cancer Translational Program
    University of Colorado Cancer Center
    Aurora, Colorado

    Consulting Agreement: Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Pfizer Inc, Seagen Inc.

    Harold J Burstein, MD, PhD
    Institute Physician, Dana-Farber Cancer Institute
    Professor of Medicine, Harvard Medical School
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Robert Dreicer, MD, MS
    Section Head, Medical Oncology
    Deputy Director, University of Virginia Cancer Center
    Associate Director for Clinical Research
    Professor of Medicine and Urology
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, Eisai Inc, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Hinova Pharmaceuticals Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Myovant Sciences, Pfizer Inc, PropellaTherapeutics Inc, TavantaTherapeutics; Contracted Research: Arvinas, Exelixis Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Hinova Pharmaceuticals Inc.

    Justin F Gainor, MD
    Director, Center for Thoracic Cancers at Massachusetts General Hospital
    Director of Targeted Immunotherapy in the Henri and BelindaTermeer Center for Targeted Therapies
    Associate Professor of Medicine at Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Oncology, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals.

    J Randolph Hecht, MD
    Professor of Clinical Medicine
    Director, UCLA GI Oncology Program
    Carol and Saul Rosenzweig Chair in Cancer Therapies Development
    Santa Monica, California

    Advisory Committee: Actym Therapeutics, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Mirati Therapeutics, Rafael Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Merck, Mirati Therapeutics, Tesaro, A GSK Company.

    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    Perelman School of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Hospira Inc, Jazz Pharmaceuticals Inc, Merck, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Inovio Pharmaceuticals Inc, Lilly, Mirati Therapeutics, Takeda Oncology, Trizell; Data and Safety Monitoring Board/Committee: Lilly, Oncocyte.

    Krishnansu S Tewari, MD
    Professor and Division Director
    Division of Gynecologic Oncology
    University of California, Irvine
    Irvine, California

    Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company.

    Sonali M Smith, MD
    Elwood V Jensen Professor of Medicine
    Chief, Section of Hematology/Oncology
    Co-Leader, Cancer Service Line
    Co-Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Exact Sciences Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Merck, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.

    Release date: July 2021
    Expiration date: July 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Lung Cancer

Genitourinary Cancers 

Chronic Lymphocytic Leukemia and Lymphomas 

Gastrointestinal Cancers

Gynecologic Cancers

Breast Cancer

Select Publications